

Ph: (214) 919-2090 or (877) 753-6878 Fax: 1 (888) 294-9434

☐ New Patient
Date

Patient Name		DOB	Weight			
Street Address:						
Phone #	_Cell #		Allergies			
ICD 10 Code:						
PHYSCIAN INFORMATION						
Prescriber's Name	iber's Name Office Contact					
Street Address	Suite #	City	State	Zip		
TelephoneLice	nse # NPI	#	DPS #	DEA #		
CLINICAL INFORMATION						
Diagnosis: D HD G10 D TD G24.	.01 Dystonia G24.	9 🗆				
CYP2D6 Genotype Testing Results if k						
*IMPORTANT: Please sent patients fa						
PRESCRIPTION INFORMATION	*(Use this area or att	tach copy of RX	(s))			
☐ Tetrabenazine 12.5mg	tablets Te	trabenazine :	25mg tablets			
Week 1:						
Week 2:						
Week 3:						
Week 4:						
Quantity: 30 days _		90 days	Refills:	:		
Maintenance: Tetr	abenazine 25mg t	ablets				
Directions: Sig:						
Quantity: 30 days		0 days		efills:		
						
ALL control	led substance quantitie	es must be hand	written in number and le	etter form		

Prescriber's Signature (signature required. NO STAMPS) Date IMPORTANCE NOTICE: This fax is intended to be delivered only to the named addressee. It contains material that is confidential, privileged, proprietary or exempt from disclosure under applicable laws. If you are not the named addressee, you should not disseminate, distribute, or copy this fax. Please notify the sender immediately if you have received this document in error and then destroy this document immediately. Medicare and Medicaid or another state funded program will not cover above mentioned products. Co-payments due at dispensing of the medication

FDA BLACK BOX WARNING: [NSAID] may cause an increased risk of serious cardiovascular thrombotic event, myocardial-infarction, and stroke, which can be fatal. This risk may increase with duration of use. Patients with cardiovascular disease or risk factors for cardiovascular disease may be at greater risk.